메뉴 건너뛰기
.. 내서재 .. 알림
소속 기관/학교 인증
인증하면 논문, 학술자료 등을  무료로 열람할 수 있어요.
한국대학교, 누리자동차, 시립도서관 등 나의 기관을 확인해보세요
(국내 대학 90% 이상 구독 중)
로그인 회원가입 고객센터 ENG
주제분류

추천
검색

논문 기본 정보

자료유형
학술저널
저자정보
김지현 (Division of Gastroenterology Department of Internal Medicine Gangnam Severance Hospital Yonsei Univ)
저널정보
대한위암학회 Journal of Gastric Cancer Journal of Gastric Cancer 제22권 제1호
발행연도
2022.3
수록면
1 - 2 (2page)
DOI
10.5230/jgc.2022.22.e7

이용수

표지
📌
연구주제
📖
연구배경
🔬
연구방법
🏆
연구결과
AI에게 요청하기
추천
검색

초록· 키워드

오류제보하기
Endoscopic submucosal dissection (ESD) is a standard treatment for gastric epithelial neoplasm, including dysplasia and early gastric cancer. Therapeutic endoscopic procedures carry increased risks of complications such as bleeding and perforation compared with diagnostic endoscopy. The joint Asian Pacific Association of Gastroenterology and Asian Pacific Society for Digestive Endoscopy practice guidelines state that, among therapeutic endoscopic procedures, ESD has a particularly high risk of bleeding [1]. The number of patients on antithrombotic therapy, including antiplatelet or anticoagulant agents, has been reported to have increased [2,3], with antithrombotic agents further increasing the risk of bleeding during ESD. Thus, the timing of antithrombotic therapy discontinuation prior to ESD is important for patients after having considered the risks of bleeding and thromboembolic events. Several clinical practice guidelines have considered the use of antithrombotic agents pre- and post-ESD [1-6]. However, the risk of bleeding and thromboembolic events can depend on individual situations. Thus, consultation with a cardiologist or neurologist in terms of the duration of discontinuation and when to resume antithrombotic therapy may be helpful [2]. Furthermore, having a marker that could predict the bleeding risk could facilitate an individualized approach. In this issue of the Journal of Gastric Cancer, Ono et al. [7] analyzed the association between the risk of bleeding post-gastric ESD and antithrombotic therapy. They evaluated the bleeding risk and the coagulation time, focusing on direct oral Xa inhibitors (DXaIs) among direct oral anticoagulants (DOACs), and investigated a molecular marker to predict the risk of bleeding. They found that the bleeding risk in a DXaIs group was higher than that in both control and antiplatelet agent groups, which was not a novel finding. The risk of bleeding in the DOACs group was reported to differ according to the DOACs withdrawal time. Moreover, the withdrawal time was less than the 48 h recommended in several guidelines [1,2,6,8]. Ono et al. [7] aimed to measure molecular markers predicting bleeding in patients on DXaIs. They analyzed the ratio of inhibited thrombin generation (RITG) based on dilute prothrombin time to determine a residual coagulation activity. They reported that the RITG was significantly higher in patients using DXaIs who hemorrhaged than in those who did not hemorrhage. Therefore, the RITG could be a marker for monitoring coagulation capacity and predicting the bleeding risk post-gastric ESD.

목차

등록된 정보가 없습니다.

참고문헌 (0)

참고문헌 신청

함께 읽어보면 좋을 논문

논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!

이 논문의 저자 정보

최근 본 자료

전체보기

댓글(0)

0